Released May 9, 2016, after the close
10-Q filed May 9, 2016, 39 days after period end · 0001193125-16-583808
Q1 2016 · 10-Q
Revenue—
Net Income-$27.06M-$27.06M N/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.75-$0.75 N/M vs Q1 2015N/M vs Q4 2015
Operating Income-$27,349,000N/M
Operating Cash Flow-$23,165,000N/M
Free Cash Flowderived-$23,204,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2016 | Q1 2015 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|
| Revenue | — | — | $171.00K | $233.00K |
| Net Income | -$27.06M | -$26.07M | -$13.69M | — |
| EPS Diluted | -$0.75 | -$0.74 | -$0.46 | -$2.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR